BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Report an Adverse Event

To report an adverse event/reaction and/or product complaint to BDSI, call 1-800-469-0261 and select option 1. Or email the information requested below to drugsafety@bdsi.com.

When choosing this option please have the following information ready:

  • Identifiable reporter
  • Identifiable patient (gender)
  • Adverse reaction and/or product complaint
  • Suspect lot number and/or dosing information
  • Callback number and/or email

To report an adverse event/reaction directly to FDA’s MedWatch program, call 1-800-FDA-1088 (1-800-332-1088) or go to www.fda.gov/Safety/MedWatch.

If you wish to be contacted by your local BDSI representative, call 1-800-469-0261 and select option 6.

BDSI routinely collects and analyzes safety information on our products, including reports from healthcare professionals and patients about Adverse Events and Product Complaints. We submit reports as appropriate to the U.S. Food and Drug Administration (FDA) which reviews these reports.

Recent BDSI News

September 11, 2020

New Scientific Information Further Highlights Differentiated Clinical Profile of BELBUCA® (buprenorphine buccal film) RALEIGH, N.C. , Sept. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients

Read more
September 3, 2020

RALEIGH, N.C. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Interim Chief Executive

Read more
August 5, 2020

Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million Second Quarter BELBUCA® Net Sales Increased 34% versus Prior Year to $32.3 Million BELBUCA and Symproic® Each Reach All Time High TRx Volume and Market Share Conference Call and Webcast Scheduled for 8:30 AM

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
October 19, 2020BDSI $3.52/ - 0%
Data provided by Nasdaq. Minimum 15 minutes delayed.